Abstract:Background: Chronic immunosuppression is a known risk factor for allowing latent tuberculosis (TB) infection to transform into active TB. Immunosuppressive/immunomodulatory therapies, while highly efficacious in the treatment of psoriasis and psoriatic arthritis, may be associated with an increased rate of active TB in patients receiving some of these therapies. Objective: Our aim was to arrive at a consensus on screening for latent TB infection in psoriasis patient treated with systemic and biologic agents. Methods: Reports in the literature were reviewed regarding immunosuppressive therapies and risk of TB. Results: Screening patients for latent TB infection before commencement of treatment is of utmost importance when beginning treatment with the tumor necrosis factor-alpha inhibitors, T-cell blockers, cyclosporine, or methotrexate. The currently recommended method for screening is the tuberculin skin test. It is preferable that positively screened patients be treated with a full course of latent TB infection prophylaxis before immunosuppressive/immunomodulatory therapy is initiated. However, in the opinion of many experts, patients may be started on the immunosuppressive/immunomodulatory therapy after 1 to 2 months, if their clinical condition requires, as long as they are strictly adhering to and tolerating their prophylactic regimen. Limitations: There are few evidence-based studies on screening for latent TB infection in psoriasis patients treated with systemic and biologic agents. Conclusions: The biologic TNF-alpha inhibitors are very promising in the treatment of psoriasis. However, because TNF-alpha is also an important cytokine in preventing TB infection and in keeping latent TB infection from becoming active disease, the use of TNF-alpha inhibitors has been associated with an increased risk of developing active TB. A higher incidence of TB has also been reported with other immunosuppressive/immunomodulatory treatments for psoriasis. It is, therefore, of utmost importance to appropriately screen all patients for latent TB infection prior to initiating any immunologic therapy. Delaying immunologic therapy until latent TB infection prophylaxis is completed is preferable. However, if the patient is adhering to his prophylactic regimen and is appropriately tolerating the regimen, therapy may be started after 1 to 2 months if the clinical condition requires.

Treatment of psoriasis in patients with hepatitis C: From the Medical Board of the National Psoriasis Foundation

Expert Consensus on the Treat-to-target Strategy for Psoriasis with Biological Agents in China

Impact of long-term systemic treatment for psoriasis on liver disease in psoriasis patients with coexisting hepatitis B virus infection

Treatment of severe psoriasis with ixekizumab in a liver transplant recipient with concomitant hepatitis B virus infection

Treatment of erythrodermic psoriasis: From the medical board of the National Psoriasis Foundation

Cyclosporine and psoriasis: 2008 National Psoriasis Foundation Consensus Conference

The acitretin and methotrexate combination therapy for psoriasis vulgaris achieves higher effectiveness and less liver fibrosis

Expert Recommendations on Treating Psoriasis in Special Circumstances (Part II)

Treatment of pustular psoriasis: From the Medical Board of the National Psoriasis Foundation

Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Moderate-to-Severe Psoriasis

Is there a relationship between psoriasis and hepatitis C? A meta-analysis and bioinformatics investigation

Clinical Experience of Combination Therapy of Infliximab and Total Glucosides of Paeony for Severe Psoriasis with Liver Disorder History

Cardiovascular Considerations and Implications for Treatment in Psoriasis: An Updated Review

Management of psoriasis in patients with inflammatory bowel disease: From the Medical Board of the National Psoriasis Foundation

Biologic Treatment Algorithms for Moderate-to-Severe Psoriasis with Comorbid Conditions and Special Populations: A Review

Hepatitis Virus Reactivation in Patients with Psoriasis Treated with Secukinumab in a Real-World Setting of Hepatitis B or Hepatitis C Infection

Hepatitis B reactivation in psoriasis patients treated with anti-TNF agents: prevention and management

From the Medical Board of the National Psoriasis Foundation: Treatment targets for plaque psoriasis

National Psoriasis Foundation consensus statement on screening for latent tuberculosis infection in patients with psoriasis treated with systemic and biologic agents

Disease Characteristics and Treatment Patterns in Veterans With Rheumatoid Arthritis and Concomitant Hepatitis C Infection

Treatment of intertriginous psoriasis: From the Medical Board of the National Psoriasis Foundation